Notice for tepotinib (as hydrochloride monohydrate) (Merck Healthcare Pty Ltd)
Active ingredients
tepotinib (as hydrochloride monohydrate)
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
film-coated tablet
Indication
For the treatment of non-small cell lung cancer (NSCLC) with genetic MET alterations
Therapeutic area
Oncology